1
Lawrence L Kunz, Richard A Klein, John M Reno, David J Grainger, James C Metcalfe, Peter L Weissberg, Peter G Anderson: Therapeutic inhibitor of vascular smooth muscle cells. NeoRx Corporation, Schwegman Lundberg Woessner & Kluth P A, March 31, 1998: US05733925 (479 worldwide citation)

Methods are provided for inhibiting stenosis following vascular trauma or disease in a mammalian host, comprising administering to the host a therapeutically effective dosage of a therapeutic conjugate containing a vascular smooth muscle binding protein that associates in a specific manner with a ce ...


2
Lawrence L Kunz, Richard A Klein, John M Reno: Therapeutic inhibitor of vascular smooth muscle cells. NeoRx Corporation, Schwegman Lundberg Woessner & Kluth P A, November 9, 1999: US05981568 (352 worldwide citation)

Methods are provided for inhibiting stenosis or restenosis following vascular trauma in a mammalian host, comprising administering to the host a therapeutically effective dosage of a cytostatic agent and/or cytoskeletal inhibitor so as to biologically stent the traumatized vessel. Also provided is a ...


3
Lawrence L Kunz: Therapeutic inhibitor of vascular smooth muscle cells. NeoRx Corporation, Schwegman Lundberg Woessner & Kluth P A, January 9, 2001: US06171609 (225 worldwide citation)

Methods are provided for inhibiting stenosis following vascular trauma or disease in a mammalian host, comprising administering to the host a therapeutically effective dosage of a therapeutic conjugate containing a vascular smooth muscle binding protein that associates in a specific manner with a ce ...


4
Lawrence L Kunz, Richard A Klein, John M Reno, David J Grainger, James C Metcalfe, Peter L Weissberg, Peter G Anderson: Therapeutic inhibitor of vascular smooth muscle cells. NeoRx Corporation, Schwegman Lundberg Woessner & Kluth P A, September 22, 1998: US05811447 (221 worldwide citation)

Methods are provided for inhibiting stenosis following vascular trauma or disease in a mammalian host, comprising administering to the host a therapeutically effective dosage of a therapeutic conjugate containing a vascular smooth muscle binding protein that associates in a specific manner with a ce ...


5
David C Anderson, A Charles Morgan Jr, Paul G Abrams, Alan R Fritzberg, Everett J Nichols: Covalently-linked complexes and methods for enhanced cytotoxicity and imaging. NeoRx Corporation, December 8, 1992: US05169933 (186 worldwide citation)

Covalently-linked complexes (CLCs) for targeting a defined population of cells, comprising a targeting protein; a cytotoxic agent; and an enhancing moiety, wherein the enhancing moiety is capable of promoting CLC-target cell interaction are disclosed. Methods for using the claimed CLCs to obtain enh ...


6
John H Priest: Oligonucleotide conjugates. NeoRx Corporation, Burns Doane Swecker & Mathis, February 21, 1995: US05391723 (178 worldwide citation)

There is disclosed an oligonucleotide strand or duplex-targeting protein conjugate, a linking group to link an oligonucleotide to a targeting protein, and a method for producing targeting protein conjugates containing oligonucleotide strands or duplexes. A suitable linker is a bifunctional phosphora ...


7
Alan R Fritzberg, Sudhakar Kasina, Ananthachari Srinivasan, Daniel S Wilbur: Metal radionuclide labeled proteins for diagnosis and therapy. NeoRx Corporation, January 30, 1990: US04897255 (127 worldwide citation)

Protein conjugated chelated metal radionuclides are provided for use in vivo. Intermediates are provided for preparing the polypeptide compositions efficiently.


8
Lawrence L Kunz, John M Reno: Therapeutic inhibitor of vascular smooth muscle cells. NeoRx Corporation, Schwegman Lundbereg Woessner & Kluth P A, December 10, 2002: US06491938 (112 worldwide citation)

Methods are provided for inhibiting stenosis or restenosis following vascular trauma in a mammalian host, comprising administering to the host a therapeutically effective dosage of a cytostatic agent and/or cytoskeletal inhibitor so as to biologically stent the traumatized vessel. Also provided is a ...


9
Lawrence L Kunz, John M Reno: Therapeutic inhibitor of vascular smooth muscle cells. NeoRx Corporation, Schwegman Lundberg Woessner & Kluth P A, October 23, 2001: US06306421 (109 worldwide citation)

Methods are provided for inhibiting stenosis or restenosis following vascular trauma in a mammalian host, comprising administering to the host a therapeutically effective dosage of a cytostatic agent and/or cytoskeletal inhibitor so as to biologically stent the traumatized vessel. Also provided is a ...


10
Lawrence L Kunz, John M Reno: Therapeutic inhibitor of vascular smooth muscle cells. NeoRx Corporation, Schwegman Lundberg Woessner & Kluth P A, May 27, 2003: US06569441 (109 worldwide citation)

Methods are provided for inhibiting stenosis or restenosis following vascular trauma in a mammalian host, comprising administering to the host a therapeutically effective dosage of a cytostatic agent and/or cytoskeletal inhibitor so as to biologically stent the traumatized vessel. Also provided is a ...